|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Mar 30, 2007. Alan R.
Gillespie, CBE, PhD (56)
Non-Executive Director, Chairman of the Audit Committee
Dr. Gillespie was appointed a director of Elan in March
1996. He is chairman of Ulster Bank Limited and chairman of the
International Finance Facility. From November 1999 until
November 2002, he was chief executive officer of CDC Group, plc
and was previously a managing director of Goldman Sachs
International.
Ann Maynard Gray (61)
Non-Executive Director, Member of the Nominating Committee
Ms. Maynard Gray was appointed a director of Elan in
February 2001. She was formerly president of Diversified
Publishing Group of Capital Cities/ABC, Inc. Ms. Gray is
also a director of Duke Energy Corporation and The Phoenix
Companies, Inc.
Gary Kennedy (49)
Non-Executive Director, Member of the Audit Committee
Mr. Kennedy was appointed a director of Elan in May 2005.
From May 1997 to December 2005, he was Group Director,
Finance & Enterprise Technology, at Allied Irish Banks,
plc (AIB) and a member of the main Board of AIB and was also on
the Board of M&T, AIB’s associate in the United States.
Prior to that, Mr. Kennedy was group vice president at
Nortel Networks
50 Elan
Corporation, plc 2006 Annual Report
Table of Contents
Financial Review
Europe after starting his management career at
Deloitte & Touche. He served on the Board of the
Industrial Development Authority of Ireland for 10 years
until he retired in December 2005. He is a director of Calyx
Group plc, the NUI Galway Development Board, and a number of
private companies. Mr. Kennedy is a chartered accountant.
G. Kelly Martin (48)
Executive Director, President and CEO
Mr. Martin was appointed a director of Elan in February
2003 following his appointment as president and chief executive
officer. He was formerly president of the International Private
Client Group and a member of the executive management and
operating committee of Merrill Lynch & Co., Inc. He
spent over 20 years at Merrill Lynch & Co., Inc.
in a broad array of operating and executive responsibilities on
a global basis.
Kieran McGowan (63)
Non-Executive Director, Lead Independent Director, Chairman
of the Nominating Committee, Member of the Audit Committee
Mr. McGowan was appointed a director of Elan in December
1998. From 1990 until his retirement in December 1998, he was
chief executive of the Industrial Development Authority of
Ireland. He is chairman of the governing authority of University
College Dublin and is a director and chairman designate of CRH,
plc, and a director of Irish Life and Permanent, plc, United
Drug, plc, Enterprise Ireland, and a number of private companies.
William Rohn (63)
Non-Executive Director, Member of the Leadership, Development
and Compensation Committee
Mr. Rohn was appointed a director of Elan in May 2006. He
is currently vice chairman of Raven Biotechnologies, Inc., and a
director of Metabasis Therapeutics, Inc., Cerus Corp and
Pharmacyclics, Inc. Previously, he was chief operating officer
of Biogen Idec until January 2005 and prior thereto president
and chief operating officer of Idec Pharmaceutical Corporation
from 1993.
Dennis J. Selkoe, MD (63)
Non-Executive Director, Chairman of the Leadership,
Development and Compensation Committee
Dr. Selkoe was appointed a director of Elan in July 1996,
following our acquisition of Athena Neurosciences, where he
served as a director since July 1995. Dr. Selkoe was a
founder of Athena Neurosciences. Dr. Selkoe, a neurologist,
is a professor of neurology and neuroscience at Harvard Medical
School. He also serves as
co-director
of the Center for Neurologic Diseases at The Brigham and
Women’s Hospital.
|
| |||||||
